MacroGenics, Inc. (MGNX)
NASDAQ: MGNX · Real-Time Price · USD
3.700
-0.170 (-4.39%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.

Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies.

In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types.

Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications.

It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MacroGenics, Inc.
MacroGenics logo
Country United States
Founded 2000
IPO Date Oct 10, 2013
Industry Biotechnology
Sector Healthcare
Employees 339
CEO Scott Koenig

Contact Details

Address:
9704 Medical Center Drive
Rockville, Maryland 20850
United States
Phone 301 251 5172
Website macrogenics.com

Stock Details

Ticker Symbol MGNX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001125345
CUSIP Number 556099109
ISIN Number US5560991094
SIC Code 2834

Key Executives

Name Position
Dr. Scott Koenig M.D., Ph.D. President, Chief Executive Officer and Director
James Karrels Senior Vice President, Chief Financial Officer and Corporate Secretary
Dr. Stephen L. Eck M.D., Ph.D. Senior Vice President of Clinical Development and Chief Medical Officer
Eric Blasius Risser Chief Operating Officer
Dr. Thomas M. Spitznagel Ph.D. Senior Vice President of Technical Operations
Dr. Ezio Bonvini M.D. Senior Vice President of Research and Chief Scientific Officer
Jeffrey Stuart Peters Senior Vice President, General Counsel and Corporate Compliance Officer
Lynn Cilinski Vice President, Controller and Treasurer

Latest SEC Filings

Date Type Title
Oct 30, 2024 8-K Current Report
Oct 22, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Sep 16, 2024 8-K Current Report
Aug 6, 2024 8-K Current Report
Aug 6, 2024 10-Q Quarterly Report
Jul 30, 2024 8-K Current Report
Jul 30, 2024 8-K Current Report
Jun 4, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
May 23, 2024 8-K Current Report
May 23, 2024 S-8 Securities to be offered to employees in employee benefit plans